SEER, INC. (SEER) Spending and interest coverage
- R&D / revenue · 12 months: Value 264.15%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 74.35%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 264.15% | Research and development expense / revenue. Period ending 2026-06-30. $37.55M ÷ $14.22M × 100 ≈ 264.15% |
| Stock-based compensation / revenue · 12 months | 74.35% | Share-based compensation / revenue. Period ending 2026-06-30. $10.57M ÷ $14.22M × 100 ≈ 74.35% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 37.55M USD | Research and Development Expense |
| Revenue | 14.22M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 10.57M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -70.83M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $37.55M | $14.22M | $10.57M | $-70.83M | (m) | 264.15% | 74.35% | (m) | (m) |
| 2026-03-31 | $41.33M | $15.17M | $12.88M | $-74.52M | (m) | 272.52% | 84.91% | (m) | (m) |
| 2025-12-31 | $43.87M | $16.58M | $15.41M | $-77.99M | (m) | 264.65% | 92.98% | (m) | (m) |
| 2025-09-30 | $46.75M | $16.38M | $18.57M | $-84.09M | (m) | 285.47% | 113.37% | (m) | (m) |
| 2025-06-30 | $48.92M | $16.29M | $21.50M | $-89.07M | (m) | 300.35% | 131.98% | (m) | (m) |
| 2025-03-31 | $49.67M | $15.31M | $25.29M | $-95.64M | (m) | 324.45% | 165.20% | (m) | (m) |
| 2024-12-31 | $50.59M | $14.17M | $28.21M | $-100.10M | (m) | 356.99% | 199.06% | (m) | (m) |
| 2024-09-30 | $49.13M | $14.61M | $29.38M | $-98.84M | (m) | 336.33% | 201.14% | (m) | (m) |
| 2024-06-30 | $49.40M | $14.74M | $31.19M | $-100.36M | (m) | 335.16% | 211.65% | (m) | (m) |
| 2024-03-31 | $50.81M | $15.67M | $33.28M | $-101.21M | (m) | 324.17% | 212.33% | (m) | (m) |
| 2023-12-31 | $53.02M | $16.66M | $34.42M | $-103.46M | (m) | 318.22% | 206.61% | (m) | (m) |
| 2023-09-30 | $54.48M | $16.83M | $34.97M | $-106.18M | (m) | 323.77% | 207.81% | (m) | (m) |
| 2023-06-30 | $52.81M | $16.62M | $35.71M | $-105.40M | (m) | 317.76% | 214.86% | (m) | (m) |
| 2023-03-31 | $49.54M | $16.23M | $34.34M | $-100.89M | (m) | 305.16% | 211.50% | (m) | (m) |
| 2022-12-31 | $45.80M | $15.49M | $33.67M | $-97.23M | $0.00 | 295.60% | 217.34% | (m) | Reported |
| 2022-09-30 | $41.38M | $13.95M | $32.18M | $-92.16M | (m) | 296.56% | 230.64% | (m) | (m) |
| 2022-06-30 | $37.57M | $12.15M | $29.90M | $-85.52M | (m) | 309.06% | 245.96% | (m) | (m) |
| 2022-03-31 | $33.63M | $9.87M | $27.95M | $-78.76M | (m) | 340.79% | 283.27% | (m) | (m) |
| 2021-12-31 | $29.12M | $6.62M | $25.93M | $-71.47M | $22.00K | 440.09% | 391.82% | -3248.77× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $18.94M | $656.00K | $7.35M | $-33.65M | $0.00 | 2887.50% | 1120.12% | (m) | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |